Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 12/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19375793 | 1.00 | GBA1 (0.56) | GBA1HRH4HRH3EPHX2CYP19A1 | |
| SCHEMBL18789724 | 0.98 | GBA1 (0.54) | GBA1HRH4HRH3EPHX2CYP19A1 | |
| SCHEMBL18493347 | 0.96 | HRH4 (0.56) | GBA1HRH4HRH3EPHX2CYP19A1 | |
| SCHEMBL18489275 | 0.96 | HRH4 (0.56) | GBA1HRH4HRH3EPHX2CYP19A1 | |
| SCHEMBL22762136 | 0.96 | HRH4 (0.56) | GBA1HRH4HRH3EPHX2CYP19A1 | |
| SCHEMBL19300362 | 0.96 | HRH4 (0.56) | GBA1HRH4HRH3EPHX2CYP19A1 | |
| SCHEMBL19479091 | 0.96 | HRH4 (0.56) | GBA1HRH4HRH3EPHX2CYP19A1 | |
| SCHEMBL18494157 | 0.96 | HRH4 (0.56) | GBA1HRH4HRH3EPHX2CYP19A1 | |
| SCHEMBL3536093 | 0.94 | HRH4 (0.55) | GBA1HRH4HRH3EPHX2CYP19A1 | |
| SCHEMBL12265820 | 0.94 | HRH4 (0.55) | GBA1HRH4HRH3EPHX2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022159688-A9 | DEGRADERS OF GRK2 AND USES THEREOF | SONATA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2022159688-A1 | DEGRADERS OF GRK2 AND USES THEREOF | CYGNAL THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| EP-2694095-B1 | COMPOSITIONS COMPRISING GLUCAGON ANALOGS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH INC (US) | 2018-03-07 | — | — | EP | disclosed |
| US-8399405-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120190818-A1 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120172311-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | Alleron therapeutics, Inc (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120040889-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | GBA1 280/4885HRH4 4460/4885HRH3 3972/4885 |
| US-20120190818-A1 | TRIAZOLE MACROCYCLE SYSTEMS | FLT3, VIP, NGLY1 | GBA1 4570/4885HRH4 1806/4885HRH3 1158/4885 |
| US-20120040889-A1 | PEPTIDOMIMETIC MACROCYCLES | ZC3HAV1, HAVCR2, ZC3HAV1L | GBA1 998/4885HRH4 2978/4885HRH3 2750/4885 |
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | GBA1 669/4885HRH4 1851/4885HRH3 2016/4885 |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | PCNA, MKI67, NFATC1 | GBA1 2876/4885HRH4 3022/4885HRH3 2281/4885 |
| US-20120172311-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | GBA1 2752/4885HRH4 4334/4885HRH3 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.